论文部分内容阅读
托拉塞米(torasemide)为磺酰尿素的衍生物,是一种新的襻性利尿剂,与速尿相比,其具半衰期长,生物利用度高,排钾低等优点。本双盲试验旨在比较它与速尿在无氮质血症的肝硬化腹水病人中的作用。材料与方法:24例确诊为肝硬化的病人随机分为托拉塞米治疗组(12例,每天一次口服10mg,共3天)和速尿组(12例,每天一次口服25mg,共3天)。所有受试者无心和肾衰竭、高血压、糖尿病、近期消化道出血、肝昏迷、肝癌和细菌性腹膜炎等并发症。
Torasemide, a derivative of sulfonylurea, is a new salvage diuretic that has the advantages of long half-life, high bioavailability, and low potassium emission compared to furosemide. This double-blind trial is designed to compare its role with furosemide in patients with cirrhosis and ascites without azotemia. MATERIALS AND METHODS: Twenty-four patients with cirrhosis were randomized into torsemide treatment group (12 patients, once daily oral administration of 10 mg for 3 days) and furosemide (12 patients, orally 25 mg once daily for 3 days ). All subjects had no heart and kidney failure, hypertension, diabetes, recent gastrointestinal bleeding, hepatic coma, liver cancer and bacterial peritonitis and other complications.